Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

279

Participants

Timeline

Start Date

December 16, 2017

Primary Completion Date

July 7, 2022

Study Completion Date

March 30, 2029

Conditions
Hematological Malignancies
Interventions
DRUG

Talquetamab

Participants will receive IV infusion or SC injection of Talquetamab.

Trial Locations (13)

4000

Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liège

10029

Mount Sinai Medical Center, New York

28040

Hosp Univ Fund Jimenez Diaz, Madrid

28223

Hosp. Quiron Madrid Pozuelo, Pozuelo de Alarcón

31008

Clinica Univ. de Navarra, Pamplona

35294

University of Alabama Birmingham, Birmingham

37007

Hosp Clinico Univ de Salamanca, Salamanca

37203

Tennessee Oncology, Nashville

80045

University of Colorado Cancer Center, Aurora

91010

City of Hope, Duarte

1081 HV

VU Medisch Centrum, Amsterdam

3584 CX

UMCU, Utrecht

08916

Hosp. Univ. Germans Trias I Pujol, Badalona

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY